Skip to content

The Aesthetic Surgery Education and Research Foundation

A Qualitative Study on the Experiences of Women With Breast Implant Illness Print

Samantha Tang, PhD; Natalie E. Anderson, PhD; Kate Faasse, PhD; William P. Adams Jr, MD; and Jill M. Newby, PhD

Aesthetic Surgery Journal, sjab215

Background: Breast implant illness (BII) is a term used to describe physical and psychological symptoms experienced by some women following breast implant surgery. Few studies have examined the experiences of women with BII—a poorly understood condition with no clear cause or treatment.

>> View on the Aesthetic Surgery Journal  Website

Non-Malignant CD30+ Cells in Contralateral Peri-Implant Capsule of Patient With BIA-ALCL: A Premalignant Step? Print

Marshall E. Kadin, MD; Haiying Xu, BA; Lisa M. Hunsicker, MD; and Yingjie Guan, MD, PhD

Aesthetic Surgery Journal
, sjab215

Background: CD30 lymphocyte activation antigen and phosphorylated STAT3 (pSTAT3) are consistent markers of tumor cells in breast implant–associated anaplastic large cell lymphoma (BIA-ALCL). We present a case of BIA-ALCL in a breast implant capsule containing clustered tumor cells expressing CD30, pSTAT3, pSTAT6, interleukin 9, and granzyme B tumor cell biomarkers. Remarkably, the contralateral breast contained many scattered large, atypical CD30+ cells surrounded by inflammatory cells, raising a suspicion of bilateral BIA-ALCL, known to occur in some patients. To clarify the diagnosis, immunohistochemistry and multilabel immunofluorescence were performed. Unlike the tumor cells, the atypical CD30+ cells of the contralateral breast lacked pSTAT3, pSTAT6, interleukin 9, and granzyme B, eliminating a diagnosis of bilateral BIA-ALCL. This case highlights the importance of interpreting CD30 staining in the context of other tumor cell biomarkers and histopathology to avoid an incorrect diagnosis of BIA-ALCL. We believe the findings also suggest the possibility of CD30 expression as an early event in the multistep pathogenesis of BIA-ALCL.

>> View on the Aesthetic Surgery Journal  Website

Granzyme B Is a Biomarker for Suspicion of Malignant Seromas Around Breast Implants Print

Marshall E Kadin, MD, John Morgan, PhD, Haiying Xu, BS, Caroline Glicksman, MD, David Sieber, MD, William P Adams, Jr, MD, Pat McGuire, MD, Mark W Clemens, MD, Archana Thakur, PhD, Lawrence G Lum, MD, DSc

Aesthetic Surgery Journal, sjaa302

Background: Granzyme B (GrB) is a serine protease secreted, along with pore-forming perforin, by cytotoxic lymphocytes to mediate apoptosis in target cells. GrB has been detected in tumor cells associated with systemic and breast implant–associated anaplastic large cell lymphoma (BIA-ALCL) but its potential use for detection of early BIA-ALCL has not been fully investigated.

>> View on the Aesthetic Surgery Journal  Website

<< Start < Prev 1 2 3 4 5 6 7 8 9 10 Next > End >>

Page 7 of 17

"I GIVE..."

Bahman Guyuron, MD
Lyndhurst, OH

“I give because plastic surgery is my passion and my business and the scientific studies supported through donations to ASERF work like Research and Development arm of any business; produce new and efficacious procedures and more importantly, assure patient safety”

The Aesthetic Society

Copyright © 2009-2018 ASERF. 11262 Monarch St., Garden Grove, CA 92841-1441 P: 800-364-2147 F: 562-799-1098